Nobel Science Meets Manufacturing in New Autoimmune Therapy Push

RESEARCH TRIANGLE PARK, NC – February 10, 2026 – A new collaboration is poised to accelerate a promising new class of treatments for autoimmune diseases, bridging the gap between Nobel Prize-winning science and the complex realities of advanced manufacturing. Kincell Bio, a specialized U.S. contract development and manufacturing organization (CDMO), has announced a partnership with RegCell, a biotechnology firm founded on the pioneering immunology research of Professor Shimon Sakaguchi.

The partnership aims to move RegCell’s innovative regulatory T-cell (Treg) therapy into clinical trials. Kincell Bio will provide the crucial process development and GMP (Good Manufacturing Practices) manufacturing support needed to turn RegCell’s scientific platform into a potential lifeline for patients suffering from conditions like autoimmune hepatitis. This alliance highlights a critical trend in biotechnology: the translation of profound scientific discoveries into viable therapies requires not just brilliant research, but also industrial-scale expertise.

From Nobel Discovery to Clinical Reality

The science underpinning RegCell’s work is rooted in decades of foundational immunology. The company’s co-founder, Professor Shimon Sakaguchi, shared the 2025 Nobel Prize for Physiology or Medicine for his discovery of regulatory T-cells, a specialized type of immune cell that acts as the body's peacekeeper, preventing the immune system from attacking its own tissues. This discovery opened up a new field of research aimed at harnessing Tregs to treat autoimmune diseases, where this natural tolerance mechanism has broken down.

RegCell’s platform represents a significant evolution of this concept. Instead of using broad immunosuppressants that can leave patients vulnerable to infections, RegCell's technology seeks to restore the body’s natural balance. It does so through a proprietary process of epigenetic reprogramming, which converts a patient's own disease-driving CD4+ T-cells into stable, antigen-specific Tregs. These reprogrammed cells are designed to target the source of the autoimmune attack with precision, re-establishing immune tolerance only where it is needed.

A key differentiator for RegCell’s approach is that it avoids gene editing and the use of viral vectors, which are common in other cell therapies. This non-gene-edited method is expected to reduce manufacturing complexity, enhance the therapy's safety profile, and potentially lower costs, making it more scalable for a wide range of autoimmune disorders.

“RegCell’s science represents a significant advancement in the treatment of autoimmune disorders, and our team is committed to providing the technical solutions and GMP execution required for clinical success,” said Bruce Thompson, PhD, President and Chief Technology Officer of Kincell Bio, in a statement.

The Manufacturing Imperative in Cell Therapy

For innovative biotechs like RegCell, developing a groundbreaking therapy is only half the battle. Creating a consistent, scalable, and regulator-approved manufacturing process for a living drug is a monumental challenge. This is where specialized CDMOs like Kincell Bio have become indispensable partners in the cell therapy ecosystem.

Launched in 2023 with a $36 million investment and recently bolstered by an additional $22 million funding round, Kincell Bio was spun out of Inceptor Bio to focus exclusively on the complexities of cell therapy manufacturing. The company operates two key facilities: a site in Gainesville, Florida, tailored for early-phase clinical programs, and a larger facility in Research Triangle Park, North Carolina, designed for pivotal studies and commercial launch supply.

Under the new partnership, RegCell will transfer its lead program to Kincell, which will optimize the manufacturing process for scalability and produce the clinical-grade material necessary for IND-enabling studies and human trials. This allows RegCell to focus on its core scientific and clinical development work while leveraging Kincell's established infrastructure and expertise.

“Our relationship with Kincell Bio is a critical part of our US strategic plan and enables us to access leading capabilities in T-cell manufacturing, as well as to focus on creating a commercially viable manufacturing process at an early stage of clinical development,” noted Michael McCullar, Ph.D., Chief Executive Officer of RegCell.

A New Frontier for Autoimmune Treatment

The market for autoimmune therapies is vast, but current treatments often come with significant drawbacks. The collaboration between RegCell and Kincell Bio enters a competitive but hopeful landscape where new technologies are seeking to move beyond broad immune suppression.

The global market for Treg therapies is projected to grow exponentially, reaching over $22 billion by 2031 as companies race to develop treatments for conditions ranging from multiple sclerosis and rheumatoid arthritis to preventing organ transplant rejection. Competitors like Quell Therapeutics and Cugene are also advancing their own Treg-based candidates through clinical trials. However, RegCell's non-gene-edited, epigenetically reprogrammed approach offers a distinct potential advantage in safety and manufacturing simplicity.

RegCell's initial focus is on autoimmune hepatitis, a condition where the body's immune system attacks the liver. With a first-in-human trial planned for 2025, the company is well-capitalized to pursue its goals, having recently secured $45.8 million in a mix of venture funding and non-dilutive government grants and strategically relocated its headquarters to the U.S. to accelerate its clinical and commercial ambitions.

“We are proud to partner with RegCell in advancing this groundbreaking new category of cell therapy,” stated Larry Pitcher, Chief Executive Officer at Kincell Bio. “RegCell’s vision for restoring immune tolerance through precisely engineered Tregs aligns perfectly with Kincell’s mission to empower pioneering cell therapy developers with agile, reliable, and high-quality CMC and manufacturing support.”

This partnership represents more than a business agreement; it is a strategic fusion of pioneering science and industrial-scale manufacturing capability. As RegCell's therapy progresses toward the clinic, its success could validate a new paradigm for treating autoimmune diseases, offering a targeted, restorative approach that could one day replace the blunt instruments of broad immunosuppression for countless patients worldwide.